BMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 34 cases where BMY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 71%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BMY's RSI Oscillator exited the oversold zone, 15 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 50%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 31 of 59 cases where BMY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 53%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on BMY as a result. In 43 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 47%.
The Moving Average Convergence Divergence (MACD) for BMY just turned positive on October 16, 2026. Looking at past instances where BMY's MACD turned positive, the stock continued to rise in 26 of 51 cases over the following month. The odds of a continued upward trend are 51%.
Following a +6.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 174 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
BMY moved below its 50-day moving average on September 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BMY crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
The Aroon Indicator for BMY entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating fairly steady price growth. BMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 78 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock worse than average.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.384) is normal, around the industry mean (-3.218). P/E Ratio (12.901) is within average values for comparable stocks, (20.770). BMY's Projected Growth (PEG Ratio) (17.786) is slightly higher than the industry average of (5.738). Dividend Yield (0.043) settles around the average of (0.042) among similar stocks. P/S Ratio (2.642) is also within normal values, averaging (4.033).
The 10-day moving average for IHE crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 56 of 70 cases where IHE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
IHE moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IHE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for IHE entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IHE's RSI Oscillator exited the oversold zone, 22 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on IHE as a result. In 64 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for IHE just turned positive on October 15, 2026. Looking at past instances where IHE's MACD turned positive, the stock continued to rise in 40 of 52 cases over the following month. The odds of a continued upward trend are 77%.
Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where IHE advanced for three days, in 287 of 345 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
IHE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
BMY | ||
|---|---|---|
OUTLOOK RATING 1..100 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | |
PROFIT vs RISK RATING 1..100 | 78 | |
SMR RATING 1..100 | 22 | |
PRICE GROWTH RATING 1..100 | 50 | |
P/E GROWTH RATING 1..100 | 71 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BMY | IHE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 50% | 2 days ago 81% |
| Stochastic ODDS (%) | 2 days ago 53% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 47% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 51% | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 56% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 55% | 2 days ago 77% |
| Advances ODDS (%) | 6 days ago 56% | 6 days ago 83% |
| Declines ODDS (%) | 2 days ago 54% | 2 days ago 77% |
| BollingerBands ODDS (%) | 2 days ago 71% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 54% | 2 days ago 82% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 1 FA rating(s) are green while .
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 6 TA indicator(s) are bullish.
BMY (@Pharmaceuticals: Major) experienced а +2.17% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.33%. For the same industry, the average monthly price growth was -4.81%, and the average quarterly price growth was +5.40%.
BMY is expected to report earnings on Oct 29, 2026.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
A.I.dvisor indicates that over the last year, IHE has been closely correlated with LLY. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if IHE jumps, then LLY could also see price increases.